Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

6

Revenue 2017

Remicade

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Remicade was produced by Johnson & Johnson, Mitsubishi Tanabe Pharma and Merck & Co..

Will biosimilars ever catch on in the US?

Will biosimilars ever catch on in the US?

Pfizer also cited a Janssen brochure that allegedly implied the biosimilar Inflectra is not interchangeable with Remicade and may pose a safety risk.

J&J earnings top expectations, but feels the squeeze in US

J&J earnings top expectations, but feels the squeeze in US Anti-inflammatory medicine Remicade also saw a sales drop  21% due to price reductions, but its still holding on to a remarkable 93% of its market share, holding out against biosimilar

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial Remicade (infliximab) facing increasing competition from biosimilars. ... TNF inhibitor Remicade’s sales fell by around 15% in the first nine months of the year to $4.1bn, mainly due to price reductions, while Tremfya sales were $369m globally

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP Sandoz’ Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics